Overview

Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer

Status:
Recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
The investigators propose to evaluate the efficacy of the combination of standard chemotherapy with bevacizumab with Pembrolizumab in women with recurrent, persistent, or metastatic cervical cancer.
Phase:
Phase 2
Details
Lead Sponsor:
University of Miami
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Bevacizumab
Carboplatin
Paclitaxel
Pembrolizumab